Cencora, Inc. (NYSE:COR) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 41.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,334 shares of the company’s stock after purchasing an additional 1,568 shares during the period. Exchange Traded Concepts LLC’s holdings in Cencora were worth $1,201,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in COR. Retirement Planning Group LLC acquired a new stake in shares of Cencora in the third quarter valued at $251,000. Ritholtz Wealth Management boosted its holdings in Cencora by 0.8% during the 3rd quarter. Ritholtz Wealth Management now owns 10,560 shares of the company’s stock valued at $2,377,000 after acquiring an additional 82 shares during the period. Gateway Investment Advisers LLC grew its position in Cencora by 9.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 4,388 shares of the company’s stock valued at $988,000 after acquiring an additional 364 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in Cencora by 5.0% during the third quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock worth $370,000 after purchasing an additional 79 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Cencora by 33.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company’s stock valued at $6,160,000 after purchasing an additional 6,900 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the topic of several recent research reports. Leerink Partners cut their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. JPMorgan Chase & Co. increased their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Evercore ISI lowered their target price on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Robert W. Baird reduced their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.44.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR stock opened at $236.60 on Thursday. The business has a 50 day moving average price of $232.42 and a 200 day moving average price of $231.15. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The stock has a market cap of $47.19 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $182.75 and a fifty-two week high of $247.66.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter last year, the company earned $2.92 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.86%. Cencora’s dividend payout ratio is presently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.